Trials
1 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet”In the company’s words, NCT06828887 on ClinicalTrials.gov
- Tested for
- MDD
- Main trialPhase 2
- “This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.”In the company’s words, NCT06828887 on ClinicalTrials.gov
- Other names
- Low-dose group · High-dose group
Other drugs for MDD
- VQW-765Vanda Pharmaceuticals · Phase 3
- ITI-1284Intra-Cellular Therapies, Inc. · Phase 3
- MethyloneTranscend Therapeutics · Phase 3
- SEP-363856Otsuka · Phase 3
- PsilocybinCOMPASS Pathways · Phase 2/3
- BuagafuranBeijing Union Pharmaceutical Factory Ltd · Phase 3
Coming up1
- 1 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Sep 2027 | Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD | |
| Phase 1Completed | 17 Dec 2024 | Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules | |
| Phase 1Completed | 19 Jan 2025 | A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET | |
| Phase 1Completed | 17 Nov 2025 | Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026